Close
What would you like to look for?
Site search
Search filters

EBL sells telecom division to Sunrise

5 September 2022

EBL has been active in the telecom business since 2000 and owns telecom networks in around 200 communities in Switzerland. At the same time, EBL has been successfully pursuing a strong expansion of its business with renewable...

Novaremed and NeuroFront enter option and license agreement for NRD.E1

25 July 2022

Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for Novaremed’s innovative non-opioid investigational drug, NRD.E1, being developed for the treatment of diabetes-related neuropathic pain and other neuropathic pain indications.

Internal investigations in sensitive industry sector completed

14 September 2021

VISCHER completes to internal investigations in particularly sensitive industry sector.

Haya Therapeutics completes CHF 18m Seed Financing Round

21 May 2021

HAYA Therapeutics SA announced the successful closing of its CHF 18m seed round.

Sale of Mestex AG to Grünenthal

21 April 2021

The previous owners of Mestex AG, a Swiss biotech company developing, sold their shares and stock options to the pharmaceutical company Grünenthal

Capricorn Holding has been acquired by Forster Gruppe and Migros Aare

9 March 2021

Capricorn Holding AG, which includes GEISER agro.com ag, active in the table fruit sector, agroSmart ag, as well as stakes in Terralog ag and vs.fruits sa, is one of the largest independent table fruit and potato logistics...

Kuros Biosciences AG completes rights offering and share placement

2 November 2020

Kuros Biosciences AG (SIX: KURN) completes a rights offering and share placement in which a total of 10,341,432 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00...

Polyphor enters into CHF 19.3 million equity-linked financing arrangement

31 August 2020

Polyphor AG has entered into an equity-linked financing arrangement with the French company IRIS to raise a gross amount of up to CHF 19.3 million over a period of two years. Under the financing instrument, IRIS will receive...

EraCal Therapeutics AG Closes Seed Financing Round

7 November 2019

EraCal Therapeutics AG, established as a spin-off from the University of Zurich and Harvard University, completes an oversubscribed seed financing round. Investors included Bernina BioInvest, Redalpine, the UZH Life Sciences Fund...

Anokion Acquires Kanyos Bio and Raises USD 40M

31 October 2019

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, acquired Kanyos Bio, Inc. and completed of a USD 40M Series B financing. The Kanyos acquisition adds KAN-101 to...